A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of secukinumab 300mg in
Chinese adults participants with active ankylosing spondylitis (AS) who have had an
inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or
intolerance to or a contraindication for NSAIDs, and who are naïve to biologic
disease-modifying anti-rheumatic drugs (bDMARD).
Phase:
Phase 4
Details
Lead Sponsor:
Tongji Hospital
Collaborators:
Wuhan Central Hospital Wuhan Hospital of Traditional Chinese Medicine